MHRA grants conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with R/R B-ALL April 30, 2025
Ivonescimab Receives NMPA Approval for 1L Treatment of PD-L1-Positive NSCLC, Based on Ph 3 Trial Demonstrating Superior Efficacy Over Keytruda April 30, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in R/R multiple myeloma April 22, 2025
US FDA Grants Full Approval of VITRAKVI (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors April 16, 2025
DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
Enhertu approved in the EU for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy April 8, 2025
TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer April 2, 2025
FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic CRPC April 2, 2025
U.S. FDA Approves CABOMETYX for Patients with Previously Treated Advanced Neuroendocrine Tumors April 2, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with muscle-invasive bladder cancer April 2, 2025
TEVIMBRA Approved in U.S. for 1L Treatment of Advanced ESCC in Combination with Chemotherapy March 11, 2025
European Commission Approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with Unresectable or Advanced HCC March 11, 2025
EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies February 25, 2025
EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma February 25, 2025
